<DOC>
	<DOCNO>NCT00758706</DOCNO>
	<brief_summary>The primary aim study investigate effect AZD1236 compare placebo ( `` inactive substance '' ) COPD patient analyse biomarkers inflammation tissue degradation blood , urine sputum .</brief_summary>
	<brief_title>A Phase IIa Study Assessing Effects AZD1236 Biomarkers Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis COPD 1 month Men postmenopausal woman Spirometry value indicate symptomatic patient Smoking history equivalent use 20 cigarette day 10 year . Any current respiratory tract disorder COPD Requirement regular oxygen therapy Acute worsen COPD ( exacerbation ) 1,5 month prior study drug administration Use oral parenteral glucocorticosteroids within 30 day use inhaled steroid 14 day prior study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>COPD</keyword>
</DOC>